FDA sets summer PDUFA dates for Acer, Kala therapies

Before the partial government shutdown blocked FDA from taking on new user fee-based applications, the agency had accepted for review two NDAs from Acer Therapeutics Inc. (NASDAQ:ACER) and Kala Pharmaceuticals Inc. (NASDAQ:KALA), respectively.